2023 World Conference on Lung Cancer (Posters)-EP12.01. L858R Exon 21 Mutation Is Associated with a Higher Risk of Brain Metastases in Patients with NSCLC Treated with TKI

EP12.01. L858R Exon 21 Mutation Is Associated with a Higher Risk of Brain Metastases in Patients with NSCLC Treated with TKI - PDF(Abstract)

Back to course

Pdf Summary

A study conducted at the Instituto Nacional de Cancerologia in Mexico aimed to understand the risk of brain metastases in patients with non-small cell lung cancer (NSCLC) treated with EGFR targeted therapy. The researchers focused on two common EGFR mutations, exon 19 deletion and L858R, to determine if there was a difference in the risk of brain metastases between the two mutations.<br /><br />The study included 324 patients with advanced NSCLC who had either an exon 19 deletion or L858R mutation and were treated with EGFR TKI between January 2013 and December 2022. Of the patients analyzed, 40.7% had baseline central nervous system (CNS) disease.<br /><br />The results showed that patients with the L858R mutation had a significantly higher risk of brain metastases compared to those with the exon 19 deletion. The median intracranial progression-free survival (icPFS) for patients with L858R was 38 months, while it was 69.7 months for patients with the exon 19 deletion. This indicates that patients with the L858R mutation had a lower icPFS.<br /><br />Additionally, in patients without brain metastases, those with the L858R mutation had a higher rate of the development of new CNS lesions compared to those with the exon 19 deletion (31.7% vs. 18.6%). This suggests that the L858R mutation may be associated with a higher risk of developing brain metastases.<br /><br />The findings of this study suggest that patients with the L858R mutation may require therapies with higher intracranial activity to prevent or treat brain metastases. Understanding the differences in risk between different EGFR mutations can help inform treatment decisions and improve patient outcomes.

Asset Subtitle

Oscar Arrieta

Meta Tag

Speaker Oscar Arrieta

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

brain metastases

non-small cell lung cancer

NSCLC

EGFR targeted therapy

EGFR mutations

exon 19 deletion

L858R mutation

risk assessment

intracranial progression-free survival

CNS lesions